Home > Riviste > The Quarterly Journal of Nuclear Medicine and Molecular Imaging > Fascicoli precedenti > The Quarterly Journal of Nuclear Medicine and Molecular Imaging 2006 December;50(4) > The Quarterly Journal of Nuclear Medicine and Molecular Imaging 2006 December;50(4):322-9

ULTIMO FASCICOLO
 

ARTICLE TOOLS

Estratti

THE QUARTERLY JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING

Rivista di Medicina Nucleare e Imaging Molecolare


A Journal on Nuclear Medicine and Molecular Imaging
Affiliated to the Society of Radiopharmaceutical Sciences and to the International Research Group of Immunoscintigraphy
Indexed/Abstracted in: Current Contents/Clinical Medicine, EMBASE, PubMed/MEDLINE, Science Citation Index (SciSearch), Scopus
Impact Factor 2,481


eTOC

 

ADVANCES IN RADIONUCLIDE THERAPY  FREEfree


The Quarterly Journal of Nuclear Medicine and Molecular Imaging 2006 December;50(4):322-9

Copyright © 2006 EDIZIONI MINERVA MEDICA

lingua: Inglese

Current status and perspectives in alpha radioimmunotherapy

Chérel M. 1, 2, Davodeau F. 1, Kraeber-Bodéré F. 1, 3, Chatal J. F. 1

1 Department of Cancerology University of Nantes, INSERM U601, Nantes, France 2 René Gauducheau Center CRLCC Nantes Atlantique, Saint Herblain, France 3 CHRU of Nantes, Nantes, France


FULL TEXT  


Systemic administration of radiolabeled antibody directed against tumor antigens in radioimmunotherapy (RIT) enables to specifically target the cancer cells and to destroy them. So far, this strategy has proven its efficiency in the treatment of some hematological cancers with antibodies labeled with β emitting radionuclides. In the last 2 decades, availability of short half life α emitters prompted to consider their use in RIT. Contrary to β particles, α particles have a short path length and display a high lineic energy transfer. Those physical characteristics open new fields of clinical applications complementary to β-RIT. To date, α-RIT is still at a preclinical stage of development: the radiolabeling methods need to be optimized to ensure in vivo stability of the radiopharmaceuticals. Some radionuclides have complex decay schemes with daughters emitting further α particles whose toxicity needs to be investigated. The modalities of administration of radiolabeled antibodies in animal models require also to be improved for delivering higher doses to tumor targets. A comprehensive analysis of the specific events occurring at cell or tissue level in response to α irradiation would be of great interest in order to define the best therapeutic association for residual disease or consolidation treatments. This approach has been proven to be efficient in increasing antitumor response either by using high doses with organ protection (kidney, bone marrow) or by a synergistic effect between α-RIT and associated treatments, such as chemotherapy.

inizio pagina

Publication History

Per citare questo articolo

Corresponding author e-mail